Novo Nordisk expands collaboration with US app company

Shortly after the US health company Amalgam received EU approval for its app for measuring how much insulin diabetes patients need to take per day, Novo Nordisk has expanded the collaboration between the two companies.

Photo: Tidsvilde Stine/Ritzau Scanpix

Danish pharmaceutical company Novo Nordisk and US health firm Amalgam will collaborate to take over the European market for apps targeting type 2 diabetes sufferers.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs